ArticleCancer immunology, immunotherapy : CII2018
Rituximab as a therapeutic option for patients with advanced melanoma.
Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Humoral immunity in cancer.Signal transduction and targeted therapy · 2026Review
- TGF-β-producing tBregs are associated with poor survival rates in PTGS2-high cancers.Cell death & disease · 2026Article
- Humoral immunity in pancreatic cancer: B-cell heterogeneity, regulatory networks, and therapeutic opportunities.Cancer metastasis reviews · 2026Review
- The Role of B Cells in Tumorigenesis and Immunotherapy.Immune network · 2026Review
- Multifaceted function of B cells in tumorigenesis.Frontiers of medicine · 2025Review
- The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications.Frontiers in immunology · 2025Review
- Targeting molecular pathways to control immune checkpoint inhibitor toxicities.Trends in immunology · 2025Review
- Review
- Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment.International journal of biological sciences · 2024Review
- Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition.Molecular cancer · 2022Review
- Article
- Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.Frontiers in immunology · 2022Article
- Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity.Frontiers in immunology · 2022Review
- Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects.Acta pharmaceutica Sinica. B · 2021Review
- B cells in lung cancer-not just a bystander cell: a literature review.Translational lung cancer research · 2021Review
- Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients.Oncoimmunology · 2021Article
- Regulatory B cells in cancer.Immunological reviews · 2021Review
- Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma.Biomedicines · 2020Review
- Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature.Therapeutic advances in medical oncology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of metastatic melanoma remains challenging, despite a variety of new and promising immunotherapeutic and targeted approaches to therapy. New treatment options are still needed to improve long-term tumour control. We present a case series of seven patients with metastatic melanoma who were treated individually with the anti-CD20 antibody rituximab between July 2014 and July 2015. Two of the patients were treated in an adjuvant setting. All patients had already received a variety of treatments. During an induction phase, the administration of four cycles of weekly rituximab 375 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.